Niagen Bioscience offers an undervalued, science-backed longevity platform with strong DTC momentum and balance-sheet strength, but must prove it can defend premium margins against generic NAD+ competition.
Overview
Niagen Bioscience, formerly ChromaDex, is a healthy-aging bioscience company centered on its proprietary NAD+ precursor Niagen®. After rebranding and divesting its non-core analytical standards business, Niagen now focuses on two revenue engines: Tru Niagen® consumer products and B2B Niagen® ingredients. The company benefits from strong scientific validation, international reach, DTC subscription growth, and expanding clinical and skincare verticals. Its key challenge is defending premium pricing and market share after patent setbacks opened the door to cheaper NAD+ alternatives.